Suspension of trading

Press Releases Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2025-07-17 pm EDT			5-day change	1st Jan Change
129.46 ^USD	+0.14%		-.--%	-

Dec. 05	Blueprint Medicines Highlights Long-Term Clinical Benefit of Avapritinib Across Indolent and Advanced Systemic Mastocytosis At 2025 Ash Annual Meeting	CI
25-07-18	Blueprint Medicines Corporation Announces Termination of Financing Agreement	CI

Press Releases

25-09-15	Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction	BU
25-08-27	Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction	BU
25-06-20	BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC	BU
25-06-03	BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC	BU
25-06-02	Sanofi acquires Blueprint Medicines for $9.1 billion	AQ
25-06-02	Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders	BU
25-06-02	BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders	BU
25-05-01	Blueprint Medicines: Q1 Earnings Snapshot	AQ
25-04-25	Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025	PR
25-04-24	Blueprint Medicines : 2024 Annual Report (a8aebb)	PU
25-03-31	Blueprint Medicines to Present at 24th Annual Needham Virtual Healthcare Conference	PR
25-02-14	Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results	AQ
25-02-13	Blueprint Medicines: Q4 Earnings Snapshot	AQ
25-02-05	Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025	PR
25-01-12	Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth	PR
24-12-18	Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference	PR
24-10-30	Blueprint Medicines : Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance Form 8 K	PU
24-10-30	Blueprint Medicines: Q3 Earnings Snapshot	AQ
24-10-16	Blueprint Medicines to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024	PR
24-09-10	Blueprint Medicines to Present at Upcoming Investor Conferences	PR
24-08-02	Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance	AQ
24-08-01	Blueprint Medicines: Q2 Earnings Snapshot	AQ
24-07-18	Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024	PR
24-07-04	CStone and Hengrui Enter into an Exclusive Promotion Agreement of AYVAKIT in Mainland China	AQ
24-06-14	BLUEPRINT MEDICINES : 2024 STOCK INCENTIVE PLAN Form 8 K	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Press Releases

Filters